/CMRX

CMRX Stock - Chimerix, Inc.

Q: What is the analyst price target for CMRX?

Analyst price target information is not currently available for CMRX.

Q: What is CMRX's market cap?

Market capitalization information is not currently available for CMRX.

Healthcare|Biotechnology|NASDAQ

$8.54+0.00%

+$0.00 (+0.00%) • Apr 21

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+0.1%upside

Target: $8.55

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CMRX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.18

52W High$8.55

52W Low$0.75

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$212,000	$324,000	$33.82M	$1.98M	$5.37M
Gross Profit	$212,000	$324,000	$33.38M	$1.51M	$-30,860,000
Gross Margin	100.0%	100.0%	98.7%	76.4%	-574.5%
Operating Income	$-96,567,000	$-93,065,000	$-60,386,000	$-173,400,000	$-44,516,000
Net Income	$-88,387,000	$-82,095,000	$172.17M	$-255,795,000	$-42,126,000
Net Margin	-41692.0%	-25338.0%	509.0%	-12925.5%	-784.2%
EPS	$-0.99	$-0.93	$1.97	$-3.01	$-0.68

Company Overview

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

1 Bullish0 Neutral/Bearish

Price Targets

Average Target

↓ 18.0% Downside

Now

Low

Average

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
May 23rd 2023	Robert W. Baird	Initiation	Outperform	$7
September 7th 2022	CapitalOne	Initiation	Overweight	$7

Earnings History & Surprises

CMRX

Beat Rate

45%

Last 20 quarters

Avg Surprise

-11.4%

EPS vs Estimate

Beats / Misses

9/7

4 met exactly

Latest EPS

$-0.25

Q2 2025

EPS Surprise History

Q3 23

+8.7%

$-0.21vs$-0.23

Q4 23

-22.7%

$-0.27vs$-0.22

Q1 24

+13.0%

$-0.20vs$-0.23

Q2 24

-19.0%

$-0.25vs$-0.21

Q3 24

0.0%

$-0.23vs$-0.23

Q4 24

-8.3%

$-0.26vs$-0.24

Q1 25

+3.8%

$-0.25vs$-0.26

Q2 25

+7.4%

$-0.25vs$-0.27

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2025	May 7, 2025	$-0.27	$-0.25	+7.4%	✓ BEAT
Q1 2025	Mar 21, 2025	$-0.26	$-0.25	+3.8%	✓ BEAT
Q4 2024	Nov 7, 2024	$-0.24	$-0.26	-8.3%	✗ MISS
Q3 2024	Aug 13, 2024	$-0.23	$-0.23	0.0%	= MET
Q2 2024	May 1, 2024	$-0.21	$-0.25	-19.0%	✗ MISS
Q1 2024	Feb 29, 2024	$-0.23	$-0.20	+13.0%	✓ BEAT
Q4 2023	Nov 2, 2023	$-0.22	$-0.27	-22.7%	✗ MISS
Q3 2023	Aug 3, 2023	$-0.23	$-0.21	+8.7%	✓ BEAT
Q2 2023	May 4, 2023	$-0.24	$-0.24	0.0%	= MET
Q1 2023	Mar 2, 2023	$-0.24	$-0.24	0.0%	= MET
Q4 2022	Nov 3, 2022	$2.14	$2.75	+28.5%	✓ BEAT
Q3 2022	Aug 8, 2022	$-0.24	$-0.27	-12.5%	✗ MISS
Q2 2022	May 16, 2022	$-0.35	$-0.28	+20.0%	✓ BEAT
Q1 2022	Mar 1, 2022	$-0.11	$-0.45	-309.1%	✗ MISS
Q4 2021	Nov 4, 2021	$-0.21	$-0.21	0.0%	= MET
Q3 2021	Aug 5, 2021	$-0.19	$-0.21	-10.5%	✗ MISS
Q2 2021	May 6, 2021	$-0.48	$-0.18	+62.5%	✓ BEAT
Q1 2021	Feb 25, 2021	$-0.20	$-0.19	+5.0%	✓ BEAT
Q4 2020	Nov 5, 2020	$-0.17	$-0.18	-5.9%	✗ MISS
Q3 2020	Aug 10, 2020	$-0.18	$-0.16	+11.1%	✓ BEAT